Loading...
•
Dec 31, 2024
AcelRx Q4 2024 Earnings Report
AcelRx (Talphera) narrowed its net loss in Q4 2024 due to reduced operating expenses, though no revenue was recognized.
Key Takeaways
In Q4 2024, Talphera (formerly AcelRx) reported no revenue, reflecting the transition in its commercial strategy. The company significantly reduced its operating expenses to $3.0 million, down from $4.6 million a year earlier. As a result, the net loss narrowed to $1.87 million, compared to $4.52 million in Q4 2023. Cash and investments stood at $8.86 million at quarter end.
No revenue was recognized in Q4 2024, down from $281,000 in Q4 2023.
Operating expenses decreased to $3.0 million, reflecting cost reductions.
Net loss narrowed to $1.87 million, or $0.07 per share.
Cash and investments totaled $8.86 million as of December 31, 2024.
AcelRx
AcelRx
Forward Guidance
Talphera expects continued advancement in its NEPHRO CRRT study following FDA protocol changes and new financing support, positioning the company to complete the study by end of 2025.
Positive Outlook
- FDA approval to reduce NEPHRO CRRT study size from 166 to 70 patients
- Expanded inclusion criteria allow broader patient enrollment
- Private placement financing up to $14.8 million secured
- Strong clinical enthusiasm for Niyad's anticoagulant potential
- New trial sites expected to boost enrollment pace in H1 2025
Challenges Ahead
- Zero revenue recognized in Q4 2024
- Ongoing net losses reflect limited commercial activity
- Execution risk tied to NEPHRO CRRT trial completion
- Stock price dependency for access to full financing tranches
- Limited operating runway without additional financing beyond trial